We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Suggests 28-Day Primary Endpoint for Clinical Trials of cIAI
FDA Suggests 28-Day Primary Endpoint for Clinical Trials of cIAI
October 5, 2012
Clinical trials of drugs to treat complicated intra-abdominal infections (cIAI) should have a primary endpoint of complete resolution of symptoms at 28 days following randomization and the absence of clinical failure, according to an FDA draft guidance.